Pyxis Diagnostics

Company Overview

Snapshot

Founded in April 2019 by Ravit Geva, Ilan Volovitz, Reut Yosef, Aviv De Morgan, Avia Zisso, and Bar Nathansohn, Pyxis Diagnostics operates with 1–10 employees. The company secured funding in one round from three investors, including Israel Innovation Authority and VLX Ventures. In November 2025, Pyxis Diagnostics ceased operations.

Business overview

Pyxis Diagnostics is developing an AI-powered cancer diagnostics platform designed to predict immuno-oncology (IO) drug response across various cancer types. The platform utilizes biological data from fresh tumor samples, including cell sorting, next-generation genetic sequencing, and proteomics, to deeply characterize cancer cells, immune cells, and stromal cells. This analysis delineates the cellular suppressive network within the tumor microenvironment, enabling machine-learning algorithms to classify responders based on differential patterns. Pyxis Diagnostics aims to enhance patient outcomes and improve the success rates of immunotherapies in both clinical settings and drug development, operating within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Digital Medical Diagnostics.

Strategic signal

In November 2025, Pyxis Diagnostics ceased operations. This event signals a significant shift in the company's trajectory, indicating that its efforts to develop an AI-powered cancer diagnostics platform have concluded. For investors and innovation teams, this highlights the inherent risks and challenges in the highly competitive and capital-intensive health tech and life sciences sector, particularly for early-stage ventures focused on complex areas like immuno-oncology drug response prediction.

Company Intelligence Q&A

What is Pyxis Diagnostics' primary focus?

Pyxis Diagnostics focuses on developing an AI-powered cancer diagnostics platform to predict immuno-oncology drug response for various cancer types and suggest alternative treatment routes.

When was Pyxis Diagnostics founded?

Pyxis Diagnostics was founded in April 2019.

What was the most recent significant operational update for Pyxis Diagnostics?

In November 2025, Pyxis Diagnostics ceased to operate.

Who are the founders of Pyxis Diagnostics?

The founders of Pyxis Diagnostics are Ravit Geva, Ilan Volovitz, Reut Yosef, Aviv De Morgan, Avia Zisso, and Bar Nathansohn.

Which investors participated in Pyxis Diagnostics' funding round?

Pyxis Diagnostics received funding from Israel Innovation Authority and VLX Ventures.